PL424773A1 - Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów - Google Patents
Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworówInfo
- Publication number
- PL424773A1 PL424773A1 PL424773A PL42477318A PL424773A1 PL 424773 A1 PL424773 A1 PL 424773A1 PL 424773 A PL424773 A PL 424773A PL 42477318 A PL42477318 A PL 42477318A PL 424773 A1 PL424773 A1 PL 424773A1
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- leukemia
- polysaccharide
- thyroid
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Przedmiotem zgłoszenia jest enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworu, charakteryzuje się tym, że antracyklina jest wybrana z epirubicyny, daunorubicyny, doksorubicyny, idarubicyny, i przy czym nowotwór jest wybrany z guzów litych wieku dziecięcego, guza Wilmsa, mięsaków, mięsaka tkanek miękkich, mięsaka Ewinga, chłoniaków, chłoniaka nieziarniczego, białaczki, ostrej białaczki, białaczki limfoblastycznej, białaczki mieloblastycznej, białaczki szpikowej, szpiczaka mnogiego, choroby Hodgkina, nowotworu piersi, raka piersi, nowotworu płuc, raka płuc, drobnokomórkowego raka płuca, nowotworu żołądka, raka żołądka, nowotworu pęcherza moczowego, brodawczakowego raka pęcherza moczowego z komórek nabłonka przejściowego, nowotworu tarczycy, raka tarczycy, raka brodawkowatego lub pęcherzykowego tarczycy, nowotworu trzustki, raka szyjki macicy, raka jajnika, raka endometrium, nowotworu nerki, kostniakomięsaka, neuroblastomy, nowotworu jelita grubego.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL424773A PL424773A1 (pl) | 2018-03-06 | 2018-03-06 | Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów |
PCT/PL2019/050014 WO2019172790A1 (en) | 2018-03-06 | 2019-03-05 | Anthracycline encapsulated with polysaccharide for use in the treatment of tumours |
CN201980017745.XA CN112165933B (zh) | 2018-03-06 | 2019-03-05 | 用于治疗肿瘤的多糖包裹蒽环霉素 |
EP19724635.8A EP3761955A1 (en) | 2018-03-06 | 2019-03-05 | Anthracycline encapsulated with polysaccharide for use in the treatment of tumours |
US16/978,476 US20210052616A1 (en) | 2018-03-06 | 2019-03-05 | Anthracycline encapsulated with a polysaccharide for use in the treatment of tumours |
KR1020207027492A KR20200128694A (ko) | 2018-03-06 | 2019-03-05 | 종양의 치료에 사용하기 위한 다당류로 캡슐화된 안트라사이클린 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL424773A PL424773A1 (pl) | 2018-03-06 | 2018-03-06 | Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów |
Publications (1)
Publication Number | Publication Date |
---|---|
PL424773A1 true PL424773A1 (pl) | 2019-09-09 |
Family
ID=66554462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL424773A PL424773A1 (pl) | 2018-03-06 | 2018-03-06 | Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210052616A1 (pl) |
EP (1) | EP3761955A1 (pl) |
KR (1) | KR20200128694A (pl) |
CN (1) | CN112165933B (pl) |
PL (1) | PL424773A1 (pl) |
WO (1) | WO2019172790A1 (pl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102300362B1 (ko) * | 2019-10-08 | 2021-09-08 | 고려대학교 산학협력단 | 간세포성 암종 특이적 항암 치료진단제 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006130455A2 (en) * | 2005-05-27 | 2006-12-07 | Royer Biomedical, Inc. | Bioresorbable polymer matrices and methods of making and using the same |
EP1917004A2 (de) * | 2005-08-19 | 2008-05-07 | Magforce Nanotechnologies AG | Verfahren zur einschleusung von therapeutischen substanzen in zellen |
PL221351B1 (pl) * | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Sposób otrzymywania nanocząstek polisacharydowych |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2550261B2 (ja) * | 1992-05-20 | 1996-11-06 | 株式会社ディ・ディ・エス研究所 | 酸化カルボキシメチルマンノグルカンードキソルビシン複合体 |
CN101653612A (zh) * | 2009-07-23 | 2010-02-24 | 复旦大学 | 利用白蛋白-葡聚糖制备的阿霉素纳米制剂及其应用 |
CN104523598B (zh) * | 2014-12-16 | 2017-11-14 | 中国科学院长春应用化学研究所 | 葡聚糖/阿霉素键合药纳米粒及其制备方法 |
KR101842059B1 (ko) * | 2016-02-05 | 2018-03-26 | 인하대학교 산학협력단 | 음이온성 작용기 및 아크릴레이트기가 도입된 광가교성 덱스트란 고분자 약물전달체 및 이의 제조방법 |
CN105727309B (zh) * | 2016-03-31 | 2019-04-30 | 中国药科大学 | 双敏感两亲性多糖-阿霉素偶联物及其药学组合物的制备和应用 |
-
2018
- 2018-03-06 PL PL424773A patent/PL424773A1/pl unknown
-
2019
- 2019-03-05 KR KR1020207027492A patent/KR20200128694A/ko unknown
- 2019-03-05 WO PCT/PL2019/050014 patent/WO2019172790A1/en unknown
- 2019-03-05 US US16/978,476 patent/US20210052616A1/en not_active Abandoned
- 2019-03-05 EP EP19724635.8A patent/EP3761955A1/en active Pending
- 2019-03-05 CN CN201980017745.XA patent/CN112165933B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006130455A2 (en) * | 2005-05-27 | 2006-12-07 | Royer Biomedical, Inc. | Bioresorbable polymer matrices and methods of making and using the same |
EP1917004A2 (de) * | 2005-08-19 | 2008-05-07 | Magforce Nanotechnologies AG | Verfahren zur einschleusung von therapeutischen substanzen in zellen |
PL221351B1 (pl) * | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Sposób otrzymywania nanocząstek polisacharydowych |
Non-Patent Citations (1)
Title |
---|
SAVITA BISHT, AMARNATH MAITRA, DEXTRAN - DOXORUBICIN/CHITOSAN NANOPARTICLES FOR SOLID TUMOR THERAPY, 2009 * |
Also Published As
Publication number | Publication date |
---|---|
EP3761955A1 (en) | 2021-01-13 |
CN112165933A (zh) | 2021-01-01 |
US20210052616A1 (en) | 2021-02-25 |
KR20200128694A (ko) | 2020-11-16 |
CN112165933B (zh) | 2024-04-16 |
WO2019172790A1 (en) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Thrumurthy et al. | Does surgery have a role in managing incurable gastric cancer? | |
Sehouli et al. | Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis | |
CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
AR061911A1 (es) | Anticuerpo antagonista para el tratamiento del cancer | |
PE20170517A1 (es) | Conjugados de anticuerpo-farmaco-anti-ptk7 | |
CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
ES2571235T3 (es) | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 | |
JP2004534741A5 (pl) | ||
PL424773A1 (pl) | Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów | |
MX2007000413A (es) | Antraciclina glicosidas liofilizadas estables. | |
DOP2009000208A (es) | Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana | |
PE20230373A1 (es) | Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo | |
Zanaboni et al. | Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: results of a phase II multicentric study | |
Narayan et al. | Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer | |
MX2020009111A (es) | Metodos para tratar cancer con una combinacion de un agente basado en platino y un conjugado de anticuerpo anti-factor tisular-farmaco. | |
Yi et al. | Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer | |
Iqbal et al. | Neoadjuvant chemotherapy in locally advanced breast cancer | |
MX2021015846A (es) | Derivados de antraciclina. | |
Ţarcă et al. | Borderline ovarian cyst treated by laparoscopic surgery | |
CA3156022A1 (en) | METHODS OF TREATING CANCER USING A COMBINATION OF A PLATINUM AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | |
Ahmad et al. | Frequency of primary solid malignant neoplasms in both sexes, as seen in our practice | |
Mombelli et al. | Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease | |
EA200600931A1 (ru) | Антитело против igf-i-рецептора | |
Nabawanuka et al. | Metastatic Breast Cancer and Hormonal Receptor Status among a Group of Women in Sub Saharan Africa | |
Francisco et al. | Multifocal Angiosarcoma of the Scalp: Review of the Literature and Report of Two Cases |